Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (Complete-PsA)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Aug 2018
At a glance
- Drugs Adalimumab (Primary) ; Disease-modifying antirheumatics
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms COMPLETE- PsA
- Sponsors Abbott Canada; AbbVie
- 16 Jun 2018 Results (as of Jun 2016; n=406; 12-month effectiveness data) presented at the 19th Annual Congress of the European League Against Rheumatism.
- 28 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 17 Jul 2017 Planned End Date changed from 1 Jun 2020 to 30 Nov 2019.